Table 4.
Response of patients to second-line treatment
| Response | S-A (n=381), n (%) | S-B (n=129), n (%) | P-value |
|---|---|---|---|
| First therapeutic evaluation | |||
| PR | 97 (25.5) | 41 (31.8) | <0.05 |
| CR + PR | 97 (25.5) | 41 (31.8) | <0.05 |
| SD | 142 (37.3) | 45 (34.9) | >0.05 |
| DCR | 239 (62.8) | 86 (66.7) | >0.05 |
| PD | 142 (37.2) | 43 (33.3) | >0.05 |
| Second therapeutic evaluation | |||
| PR | 80 (21.0) | 33 (25.6) | >0.05 |
| CR + PR | 80 (21.0) | 33 (25.6) | >0.05 |
| SD | 84 (22.0) | 31 (24.0) | >0.05 |
| DCR | 164 (43.0) | 64 (49.6) | >0.05 |
| PD | 217 (57.0) | 65 (50.4) | >0.05 |
Abbreviations: CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; DCR, disease control rate; S, second-line treatment; a, patients who were treated with chemotherapy without bevacizumab; B, patients who were treated with chemotherapy with bevacizumab.